Over 20 years' experience of drug discovery with strong achievements in diabetes and oncology.• Over 10 years experiences on Kras G12Ci. Chemistry leader and the inventor of clinical candidate ERAS-3490, a CNS-penetrant G12Ci at Erasca Delivered Kras G12Ci, ARS-3248 as a team member at Wellspring Chemistry leader of Kras G12D program, filed first ever Kras G12D patent at Wellspring Chemistry leader of pan-Kras program, discovered reversible and covalent inhibitors at Erasca• Served as a chemistry leader of DPP4 project. Developed "Two-in-One"​ design concept that produced Alogliptin (J.Med. Chem., 2007, 50, 2297-2300), Trelagliptin (SYR-472) and SYR-619 in Phase II. This accomplishment played significant part for the $270MM acquisition of Syrrx by Takeda. 1. NDA of Alogliptin was filed in Jan. 2008, approved (Nesina® in Japan) on April 16, 2010. It was approved in US Jan 25, 2013 as three forms: Nesina (alogliptin) tablets, the fixed-dose combinations Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone). 2. NDA of Zafatek® (Trelagliptin , the world's first once-weekly DPP4 inhibitor) was submitted for Type II diabetes treatment in Japan on Mar. 7, 2014 and approved in Japan on Mar. 26, 2015.• Recipient of Excellence in Structure Based Drug design Award in 2003 at Syrrx.• Recipient of Takeda Global Award in 2008.• 40+ issued & pending patentsSpecialties: • Delivery of 2 marketed drugs, multiple clinical candidates.• Medicinal chemistry: CNS drug, covalent inhibitors, hits generation, lead optimization, pre-clinical development, and candidate selection. And experience of PROTAC and DEL with CRO.• Structure-based drug design and Fragment-based drug design.• Project leadership. led multi-functional teams from chemistry, in vitro / in vivo pharmacology, structure biology, computational science, biophysical characterization, and DMPK. • Supervisor & mentor PhD/MS/BS scientists.• Small molecule patent applications.• Management of CROs (up to 30 FTEs) in China (Wuxi, BioDuro-Sundia& Viva) and Poland (Selvita).• 40+ publications & patents.• Therapeutic area: diabetes, oncology, chronic kidney disease.